Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Revenue down 9% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer

1Q Revenues: $11.4 billion (-9%)

1Q Earnings: $2.3 billion (-15%)

Comments: Global Vaccines sales were flat at $925 million in the quarter. Consumer Healthcare sales were down 6% to $761 million. Global Oncology revenue was $488 million, up 7%, driven by Xalkori (+66% to $88 million) and Inlyta (+40% to $88 million). Lyrica sales were $1.2 billion, up 8%. Alliance revenue was down 71% to $213 million.Sales declines were attributed to the expiration of the co-promotion term for Enbrel in the U.S. and Canada, the ongoing expiration of the Spiriva collaboration in certain countries, the loss of exclusivity for Detrol LA in the U.S., and the continued erosion of Lipitor (-27% to $457 million). R&D expenses were flat at $1.6 billion.      

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters